Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.

Advocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of ...

SMN1 replacement using AAV9 has improved survival and motor outcomes in spinal muscular atrophy (SMA), but inefficient CNS delivery necessitates high systemic doses, potentially narrowing the ...

Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting specialized nerve cells that control voluntary muscle movement, according to the Muscular Dystrophy Association (MDA). It can ...

A study of 37 SMA patients in Milan finds serum myostatin correlates with motor function and disease severity, while Smad3 ...

When evaluating a patient's muscle strength, muscle weakness is observed.Therefore, exercise therapy aimed at strengthening ...

A recent Harvard study introduces a new method for treating spinal muscular atrophy. The study used "base editing" to target the disease's root cause by modifying the survival motor neuron gene. For ...

You might not think of diabetes when you think of muscle function. But a common diabetes drug that regulates blood sugar can also prevent muscle atrophy and muscular fibrosis—which can help the ...

Muscle atrophy is a consequence of not using your muscles enough. When you stop working a certain muscle, your body repurposes the protein in it for other bodily functions. As a result, the unused ...